Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Intra-Cellular Therapies stock leapt more than 30% Monday morning, after Johnson & Johnson agreed to buy the ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. FDA for TAR-200 for the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following ...

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...

RARITAN, N.J. - Johnson & Johnson (NYSE:JNJ) has begun the process for U.S. Food and Drug Administration (FDA) approval of TAR-200, a new treatment option for high-risk non-muscle-invasive bladder ...

Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...

In an ironic twist of fate, biohacker Bryan Johnson discovers that the drug he used to freeze time was possibly ...

Bryan Johnson, the tech whiz turned anti-aging aficionado, shells out around $2 million a year trying to outsmart the Grim ...